Severity of current SARS-CoV-2 variants is not linked to the number of mutations

New research from UNC Charlotte’s Center for Computational Intelligence to Predict Health and Environmental Risks (CIPHER) has found that the two most prevalent strains of the virus that cause COVID-19, SARS-CoV-2 variants BA.2.86 and JN.1, are not significantly better than their predecessor Omicron at evading immune responses and causing infections despite having a high number of mutations compared to previous variants.

Exclusive: mRNA CDMO Vernal Biosciences secures $20M to continue its buildout

Vermont may be known for maple syrup and Ben & Jerry’s ice cream, but one manufacturer wants the Green Mountain State to become a producer

June 15, 2023

Redi Health Secures $14M to Transform Patient Support Programs

What You Should Know: – Redi Health, an innovator in digital health solutions, announced today the successful closing of a $14 million Series B funding

February 29, 2024

Contineum says it will seek $136M in IPO to back its mid-stage neuro drug

Contineum Therapeutics has set a price range for its upcoming IPO and plans to sell 8.8 million shares between $16 and $18 apiece. Its expected

April 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.